Amalgamated Bank purchased a new position in Solventum Co. (NYSE:SOLV – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 45,015 shares of the company’s stock, valued at approximately $2,380,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in SOLV. EverSource Wealth Advisors LLC acquired a new stake in shares of Solventum in the first quarter valued at about $30,000. Deseret Mutual Benefit Administrators purchased a new position in Solventum in the 2nd quarter valued at about $25,000. Richard W. Paul & Associates LLC acquired a new stake in Solventum in the 2nd quarter worth about $26,000. Family Firm Inc. purchased a new stake in Solventum during the 2nd quarter worth approximately $26,000. Finally, Partnership Wealth Management LLC acquired a new position in shares of Solventum during the second quarter valued at approximately $26,000.
Solventum Stock Down 0.1 %
Shares of SOLV stock opened at $70.04 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90. The stock’s 50-day moving average price is $61.85. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. The Goldman Sachs Group boosted their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Morgan Stanley reduced their target price on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Bank of America decreased their price target on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 25th. BTIG Research began coverage on shares of Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. Finally, Argus assumed coverage on Solventum in a report on Monday, June 24th. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $58.25.
Check Out Our Latest Stock Report on Solventum
Solventum Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Articles
- Five stocks we like better than Solventum
- How to invest in marijuana stocks in 7 steps
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Investing in Commodities: What Are They? How to Invest in Them
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.